Therefore, degradation of the high molecular weight HA into smaller fragments may contribute to tumour progression in ESCC and should be investigated in future studies.
the egf receptor (egfr, erbb1) is overexpressed in 40% to 90% of escc tumours and overexpression of egfr is associated with a poor prognosis [42 , 43].